Table 4.
Phosphorylated FLT3 | No. of patients | No. (%) with CR/CRp |
---|---|---|
Patients with samples available for analysis | 79 | 21 (26.6) |
Inhibited at aplasia assessment | 46 | 18 (39.1) |
Not inhibited at aplasia assessment | 33 | 3 (9.1) |
Inhibited both at aplasia and outcome assessments | 21 | 12 (57.1) |
The difference in the CR/CRp rate between those who were inhibited at the aplasia assessment and those who were not was highly significant (P = .004; Fisher exact test).